CD274 and cancer: More importantly, the introduction of Met endowed MS NPs with the ability to decrease PD-L1 expression in cancer cells, thereby effectively awakening the host's immune system compared with the antibody drug anti-PD-L1 that function by conformational blockade on membranous PD-L1.